SecBot SecBot
SECBOTREPLAY Home › Report › ESPR

ESPR · Esperion Therapeutics entered into a definitive agreement to be…

Esperion Therapeutics, Inc. · DEFA14A filed May 1, 2026 at 16:00 ET

At the news

BULLISHIMPACT 7/10

DEFA14A filed May 1, 2026 at 16:00 ET

Esperion Therapeutics entered into a definitive agreement to be acquired by ARCHIMED for $3.16 per share in cash, plus contingent milestone payments of up to $100 million tied to future net sales performance. The transaction is expected to close in the third quarter of 2026, subject to shareholder and regulatory approvals.

  • Acquisition price of $3.16 per share in cash
  • Contingent milestone payments of up to $100 million in aggregate
  • Expected closing in Q3 2026
  • Agreement and Plan of Merger dated May 1, 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access